The date of the IPO may be around 3 years away and the company is yet to file the DRHP. As of now, only the broad strategy and the approximate fund requirement and valuations have been worked out, subject to change.
Global bio-similars market is expected to triple to $35.7 billion by 2025. The segment is experiencing a very significant growth due to rising cases of chronic diseases and the increasing demand for bio-similars on account of their cost-effectiveness
The date of the IPO may be around 3 years away and the company is yet to file the DRHP. As of now, only the broad strategy and the approximate fund requirement and valuations have been worked out, subject to change.
Global bio-similars market is expected to triple to $35.7 billion by 2025. The segment is experiencing a very significant growth due to rising cases of chronic diseases and the increasing demand for bio-similars on account of their cost-effectiveness